DV
Dividend Vision

JANX — Janux Therapeutics, Inc.

Janux Therapeutics, Inc. (JANX)

Total return is -35.9% over the past 5.2 years, 132.3 points behind SPY at 96.4%. Its deepest 1-year drawdown was 64.9%.

JANX is an equity fund that holds shares of Janux Therapeutics, Inc., a stock-type fund launched in June 2021. The fund carries no distribution rate, reflecting the company's focus on growth rather than income generation. This fund appeals primarily to growth-oriented investors seeking exposure to the therapeutics sector rather than those prioritizing dividend income.

JANX key facts

Asset type
Stock
Asset class
Equity
Inception date
06/11/2021
Distribution frequency
None
Last close
$16.12
Market cap
$985,524,800
Average volume
441529.0
Beta
2.507
Payout ratio
0.0
Forward P/E
0.0
EPS
$-1.65